drugset / Trial / NCT01876446
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Phase 2
Completed
38 enrolled
Roswell Park Cancer Institute
National Cancer Institute (NCI) · collabNektar Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well pegylated irinotecan NKTR 102 works in treating patients with small cell lung cancer that has returned after a period of improvement. Pegylated irinotecan NKTR 102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2013-08-29
- Primary completion
- 2017-07-18
- Completion
- 2020-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etirinotecan Pegol | Other / unclassified | — | Intravenous |